Document Type

Poster Presentation

Publication Date

12-2024

Department

Pharmacy

Abstract

Dalbavancin is a lipoglycopeptide approved for the treatment of acute bacterial skin and soft tissue infections caused by gram-positive microorganisms.

Used off-label in the management of infective endocarditis in IV drug users, as well as in osteomyelitis infections.

Extremely long half-life of greater than a week.

Potential cost-effective option for susceptible gram-positive infections and increased patient compliance.

Comments

Poster presented at the ASHP Midyear Clinical Meeting & Exhibition in New Orleans, December 8-12, 2024

Additional Files

Share

COinS